drugset / Trial / NCT06615284
A Study of Atorvo+™ in Healthy Adult Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+™ in healthy adult participants. .
Timeline
- Start
- 2025-01-28
- Primary completion
- 2025-05-14
- Completion
- 2025-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 100 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 200 mg | Oral |